Free Trial
NASDAQ:VERA

Vera Therapeutics Q4 2024 Earnings Report

Vera Therapeutics logo
$23.22 -0.25 (-1.07%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$23.46 +0.25 (+1.06%)
As of 04/25/2025 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vera Therapeutics EPS Results

Actual EPS
-$0.72
Consensus EPS
-$0.83
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Vera Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vera Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, February 26, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Vera Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Friday, May 9, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Vera Therapeutics Earnings Headlines

Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Guggenheim Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
See More Vera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email.

About Vera Therapeutics

Vera Therapeutics (NASDAQ:VERA), a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

View Vera Therapeutics Profile

More Earnings Resources from MarketBeat